was conducted. IgE to peanut component proteins (Ara h1, h2, h3, h8, and h9) was measured. Sensitization was defined as IgE > _ 0.35 kU A /L. PCT data were analyzed using descriptive statistics (mean 6 standard deviation, frequency/percent, median [IQR]). RESULTS: Among the 450 patients, h2 sensitization was most prevalent (58%). Sensitization to h1 was next highest at 42.4% followed by h3 (29.8%), h8 (13.8%) and h9 (9.8%). We observed higher proportions of PCT sensitization for all components in males. Sensitization to h2 was the most common in all age strata as follows: 0-3 (n5144), 3-6, (n556), 6-9 (n567), 9-12 (n558), 12-15 (n533), and 15-21 (n523) with 56.9%, 56.0%, 59.7%, 63.8%, 54.6%, and 60.9% of participants sensitized, respectively. 109 (24.2%) patients were sensitized to Ara h1, h2 and h3. Ara h8 or h9 mono-sensitization was present in 25 (5.6%) individuals, with higher rates in the older strata: 12-15 (15.2%) and 15-21 (13.0%). CONCLUSIONS: We found that h2 is the most common component associated with sensitization and did not vary by age in contrast to sensitization to Ara h8 and h9. Mono-sensitization to Ara h 8 and h9 was more common in older children.
Component Resolved Diagnostics in Patients with Peanut Allergy versus Peanut Sensitization
Yasmin Hamzavi Abedi, MD RATIONALE: Peanut-specific-IgE(PN-sIgE) and peanut component resolved diagnostics(CRD) are often ordered simultaneously in evaluating for peanut allergy. This study examined PN-sIgE and association with CRD in patients with and without history of clinical reactivity. METHODS: A retrospective chart review of 196 children who had PNsIgE and CRD testing in an outpatient setting, was performed. 98 patients had a history of an IgE mediated reaction to peanut and 98 did not. The Fisher's exact test was used to assess the relationship between CRD(arah 1,2,3 and 9<0.35kUA/L)and PN-sIgE at different cutoff levels(2kUA/ L,5kUA/L and 14kUA/L);McNemar's test was used to assess agreement between CRD and PN-sIgE. Logistic regression was applied to examine differences in the findings between patients with and without history of clinical reactivity. RESULTS: CRD with arah1,2,3 and 9 <0.35kUA/L, regardless of arah 8, was significantly more likely to be associated with lower PN-sIgE levels at each cutoff point evaluated: PN-sIgE<14kUA/L versus > _14 kUA/L(30% vs. 4%, p<0.0004), <5kUA/L vs. > _5kUA/L(38% vs. 6%, p<0.0002), and <2kUA/L vs. > _2kUA/L(59% vs. 6%, p<0.0001). These findings were not significantly different between patients with and without a history of clinical reactivity. CONCLUSIONS: CRD values correlate with PN-sIgE. Regardless of clinical history, if a CRD(arah1,2,3 and 9) cutoff of <0.35kUA/L is used as a clinical decision point to assess risks of oral challenge, then a PNsIgE>2kUA/L is unlikely to meet the cutoff. The decision to obtain peanut CRD should be made after evaluation of the total PN-sIgE. Larger studies are needed to identify optimal CRD cutoff points.
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Safety of oral immunotherapy in addition to omalizumab in patients with severe allergy to cow's milk proteins Laura Feijoo Paz, MD, Ruth Maria Barranco, MD, Jesus F. Fernandez Crespo, P.h.D, and Maria Del Carmen Dieguez, MD, PhD; Hospital Universitario 12 de Octubre, Madrid, Spain. RATIONALE: Omalizumab in addition to oral immunotherapy (OIT) could be a safe alternative in patients with severe persistent allergy to cow's milk proteins (CMA). METHODS: Case series of 5 patients (3 women), with median age 18 years(17-19) with CMA from childhood. All patients had severe anaphylactic reactions after unnoticed milk traces intakes, with high impact on their quality of life: 3 anaphylactic shock, 3 grade II anaphylactic reactions (Brown's classification) and many grade I reactions. Median specific IgE for casein and milk was >100 KU/l. OIT protocol consists of two phases:Build-up: After four mounths in treatment with omalizumab, we performed a milk oral challenge. Subsequently weekly dose increases were made to reach 250 ml (maintenance dose), starting with the last dose tolerated.Maintenance: Dairy products are introduced progressively into the diet.They were given medication and instructions in case of allergic reaction as well as a 24-hour contact telephone number. RESULTS: All patients achieved 250 ml daily dose between 12-16 weeks (median 13). Eight reactions were reported in build-up phase, but 4 slight cutaneous reaction were in the same patient. Only 2 anaphylactic reactions were reported (grade II), one in build-up and the other in maintenance phase.All patients maintain daily intake of 250 ml of milk and free diet of dairy products. In one of them, with well controled asthma, omalizumab was delayed at 6 weeks, maintaining tolerance of diet with cow's milk. CONCLUSIONS: Omalizumab in addition to OIT could be a safe therapeutic option in patients with persistent and severe CMA.
